Oramed Pharmaceuticals Inc. today announced it has completed patient enrollment for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D), surpassing its target of 675 patients with 710 patients enrolled. ORA-D-013-1 is the larger of Oramed’s two Phase 3 studies being conducted under U.S….
eTurboNews izindatshana ezababhalisi kuphela. Ukubhalisa kuyinto MAHHALA.
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- today announced it has completed patient enrollment for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D), surpassing its target of 675 patients with 710 patients enrolled.
- .
- ORA-D-013-1 is the larger of Oramed’s two Phase 3 studies being conducted under U.
